Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Circadin (melatonin) for sleep disturbances in children with neurodevelopmental disabilities
2013-001832-23Phase 3
- Sponsor
- Neurim Pharmaceuticals
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sleep disorder comparing Circadin 2/5 mg with Placebo (2 arms). Primary endpoint: Total sleep time (TST).
02
Drugs
melatonin
03
Conditions
sleep disorder
Beyond the preview
Go deeper on 2013-001832-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001832-23.